Brachytherapy Alone for Intermediate-Risk Prostate Cancer Brachytherapy Alone for Intermediate-Risk Prostate Cancer
Patients with favorable intermediate-risk prostate cancer can be treated with radioactive-seed brachytherapy alone and thus be spared additional late toxicity associated with the usually standard delivery of external-beam radiation first.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 29, 2016 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
IsoRay settles class action shareholders suit for $3.5m
IsoRay (NYSE:ISR) said it inked a $3.5 million settlement deal related to a class action suit brought against it by shareholders in June.
The Richland, Wash.-based company is facing putative class-action lawsuits from investors, accusing the company of making false or misleading statements about a clinical trial of its Cesium 131 brachytherapy seeds designed to treat cancer in a press release released in May.
In an SEC filing posted today, IsoRay said it entered the settlement deal against it and its former CEO through which, if it becomes final, the company agrees to pay $3.5 million.
The company stipulated that the...
Source: Mass Device - September 27, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Legal News Oncology IsoRay Source Type: news
IsoRay agrees to settle shareholder lawsuit
Medical isotope developer IsoRay and its former CEO have signed an agreement...Read more on AuntMinnie.comRelated Reading:
IsoRay revenue falls, net loss edges up in Q4
IsoRay touts brain brachytherapy study results
IsoRay revenue edges higher, but net loss grows
IsoRay taps new VP of sales, marketing
IsoRay posts mixed Q2 results (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 27, 2016 Category: Radiology Source Type: news
IsoRay, Inc. Enters Into Agreement to Settle Class Action Shareholder Litigation
RICHLAND, Wash., Sept. 27, 2016 -- (Healthcare Sales & Marketing Network) -- IsoRay, Inc. ("IsoRay") (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment o... Devices, Oncology, Litigation IsoRay, brachytherapy, radiotherapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 27, 2016 Category: Pharmaceuticals Source Type: news
iCAD touts brachytherapy research at ASTRO 2016
At the American Society for Radiation Oncology (ASTRO) meeting, iCAD is touting...Read more on AuntMinnie.comRelated Reading:
iCAD president resigns
iCAD shows revenue decline in Q2
iCAD adds to customer base
iCAD integrates with Fuji digital mammo
iCAD to launch skin cancer treatment tool for Xoft (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 26, 2016 Category: Radiology Source Type: news
IsoRay revenue falls, net loss edges up in Q4
Medical isotope developer IsoRay Medical saw a decline in fourth-quarter revenue...Read more on AuntMinnie.comRelated Reading:
IsoRay touts brain brachytherapy study results
IsoRay revenue edges higher, but net loss grows
IsoRay taps new VP of sales, marketing
IsoRay posts mixed Q2 results
IsoRay CEO to retire (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 9, 2016 Category: Radiology Source Type: news
FDA releases June 2016 510(k) clearances
510(K) SUMMARIES OR 510(K) STATEMENTS FOR FINAL
DECISIONS RENDERED DURING THE PERIOD June 2016
TOTAL 510(k)s THIS PERIOD 258
TOTAL WITH SUMMARIES 235
TOTAL WITH STATEMENTS 23
DEVICE: ORAL BOND
STEINER LABORATORIES 510(k) NO: K142130(Traditional)
ATTN: GREGORY G STEINER PHONE NO : 866 3171348
1051 Olsen Street, Building 3611 SE DECISION MADE: 06-JUN-16
Henderson NV 89011 510(k) SUMMARY AVAILABLE FROM FDA
DEVICE: QiF Blood and Fluid Warmer
Quality in Flow Ltd. 510(k) NO: K150404(Traditional)
ATTN: Neta Sherman PHONE NO : 972 54 6600146
3A Bazel ...
Source: Mass Device - August 31, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Food & Drug Administration (FDA) Regulatory/Compliance Source Type: news
StemCells soars 600% on reverse merger with Israel ’ s Microbot Medical
Shares in StemCells (NSDQ:STEM) initially soared some 600% this week after the company initiated a reverse merger with Microbot Medical, after the failure of a Phase II trial of StemCells’ spinal cord injury treatment.
The merger also saw the resignation of CEO Ian Massey, CFO Gregory Schiffman and a trio of board members, as the team led by Microbot chairman & CEO Harel Gadot prepares to take over. Kenneth Stratton was tapped to serve as interim president, effective August 15.
The reverse merger sent STEM shares up 602.7% to a $2.60 close August 16, the day the deal was announced; the stock has since falle...
Source: Mass Device - August 19, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Mergers & Acquisitions Robotics Microbot Medical StemCells Source Type: news
Cianna nets FDA OK for radar system
Brachytherapy firm Cianna Medical has received an additional 510(k) clearance...Read more on AuntMinnie.comRelated Reading:
Cianna highlights SAVI Scout results at SBI
Cianna advances 2 SAVI Scout studies
Cianna nets FDA OK for SAVI Scout
Cianna promotes SAVI results at ASCO BCS
Cianna touts breast brachy results at ASBrS show (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 18, 2016 Category: Radiology Source Type: news
High-dose radiation therapy as effective as surgery for aggressive prostate cancer
This study was the first of its kind to directly compare outcomes between radiation-based treatments and surgery for patients with cancers that are Gleason score nine or 10 (the highest score possible, which represents the most aggressive form of cancer).
BACKGROUND
Prostate cancer is the most common form of cancer among men in the United States, with nearly 180,000 new cases expected to be diagnosed in 2016 alone. Therefore, identifying the optimal treatment strategies for this malignancy is particularly important.
In the past oncologists suggested that surgery and radiation-based treatments offer equivalent outcomes. How...
Source: UCLA Newsroom: Health Sciences - August 6, 2016 Category: Universities & Medical Training Source Type: news
Medical News Today: Internal radiation therapy: Better response in metastatic colorectal cancer patients
New analysis shows patients with metastatic colorectal cancer treated with radiation therapy show better response than those receiving chemotherapy alone. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 10, 2016 Category: Consumer Health News Tags: Radiology / Nuclear Medicine Source Type: news
C4 touts MRI-guided prostate brachytherapy study
Image-guided technology developer C4 Imaging said that a recent research study...Read more on AuntMinnie.comRelated Reading:
C4 raises $1.3M for multimodality marker
C4 Imaging nets 510(k) clearance for MRI marker (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 6, 2016 Category: Radiology Source Type: news
Brachytherapy pioneer Haakon Ragde, M.D., chosen as ASTRO 2016 Honorary Member
(American Society for Radiation Oncology) The American Society for Radiation Oncology (ASTRO) has selected Haakon Ragde, M.D., as its 2016 Honorary Member, the highest honor ASTRO bestows on distinguished cancer researchers, scientists and leaders in disciplines other than radiation oncology, radiobiology or radiation physics. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 28, 2016 Category: Global & Universal Source Type: news
IsoRay touts brachytherapy brain cancer trial
IsoRay (NYSE:ISR) today released results from a prospective trial of intraoperative brachytherapy using its Cesium-131 brachytherapy seeds, touting that 95% of treated tumors showed no regrowth at the operative site.
The study examined the use of the IsoRay’s seeds for treating recurrent aggressive meningiomas by applying seeds embedded in collagen tiles directly to brain tissue after tumor removal. IsoRay called the technique the “GammaTile” approach, but clarified that it is not commercially available.
A total of 95% of the treated tumors showed no radiographic evidence of regrowth of the tumor at the ...
Source: Mass Device - June 21, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Neurological Radiosurgery IsoRay Source Type: news
IsoRay touts brain brachytherapy study results
Medical isotope developer IsoRay Medical is highlighting findings from a prospective...Read more on AuntMinnie.comRelated Reading:
IsoRay revenue edges higher, but net loss grows
IsoRay taps new VP of sales, marketing
IsoRay posts mixed Q2 results
IsoRay reports flat sales
IsoRay picks new distributor for Australia, New Zealand (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 21, 2016 Category: Radiology Source Type: news
